Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael McDaniel

Physician Assistant Thomson, GA Physician Assistant

NPI 1932327996 CMS profile 11121006

315 Fluker St, Thomson, GA 30824

Open in the dashboard

General payments

$3,781

270 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael McDaniel of Thomson, GA is reported in the CMS Open Payments database as having received $3,781 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $599 39
2024 General $906 60
2023 General $644 52
2022 General $867 64
2021 General $767 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael McDaniel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michael McDaniel were reported at $599. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michael McDaniel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $767 $132 $37–$438 $132
2022 $867 $155 $48–$522 $149
2023 $644 $167 $52–$557 $160
2024 $906 $178 $55–$600 $164
2025 $599 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,157 108 payments
  2. Novo Nordisk Inc $813 57 payments
  3. Pfizer Inc. $269 16 payments
  4. Lilly USA, LLC $135 8 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $135 7 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $125 9 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $110 6 payments
  8. Supernus Pharmaceuticals, Inc. $85 3 payments
  9. ITI, Inc. $85 5 payments
  10. AstraZeneca Pharmaceuticals LP $84 6 payments
  11. Other $784 45 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,781 270 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $650 47 payments
  2. Ozempic $637 51 payments
  3. VRAYLAR $413 26 payments
  4. UBRELVY $359 38 payments
  5. NURTEC ODT Pain $203 12 payments
  6. QULIPTA $191 29 payments
  7. NURTEC ODT Primary Care $142 10 payments
  8. Kerendia $135 7 payments
  9. LINZESS $127 17 payments
  10. PAXLOVID $96 6 payments
  11. Other $2,140 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 208 drugs

Part D claims

19,638

Median for Physician Assistant: 241

Drug cost

$1,816,542

Median for Physician Assistant: $4,110

Branded share of claims

20%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 267 $359,543
Ozempic Semaglutide Brand 243 $248,151
Eliquis Apixaban Brand 191 $219,463
Farxiga Dapagliflozin Propanediol Brand 89 $97,950
Januvia Sitagliptin Phosphate Brand 66 $83,291
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 102 $70,699
Vraylar Cariprazine Hcl Brand 37 $63,175
Linzess Linaclotide Brand 63 $56,610
Rybelsus Semaglutide Brand 21 $49,159
Prolia Denosumab Brand 22 $37,892

The 10 drugs with the highest cost, of 208 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$20,131

Of which drugs: $1,820

Medicare patients

210

Average age 73

Services billed

2,890

113 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 36%
Ischemic heart disease 31%
Depression 27%
COPD 20%
Heart failure 15%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 43 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $167
$167 37 —
RYBELSUS
  • Novo Nordisk Inc $94
$94 21 —
Ozempic
  • Novo Nordisk Inc $94
$94 243 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $85
$85 — —
NURTEC ODT
  • PFIZER INC. $77
$77 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record